Fred C. Buffett Professor of Medicine and Surgery, University of Chicago Medicine
Oncology
Dr. Walter M. Stadler, MD
|
|
Give Review
Walter Stadler practices Oncology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine is ranked 7 in research and 57 in primary care medicine He received 6 awards: "America's Top Doctors", "Chicago Magazine: Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification", "Fellow (FACP)" and "Super Doctor". Walter Stadler is also published. He has 100 publications published. The lastest publication: "Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.' Doctor Walter M. Stadler, MD accepts all Medicare patients.
Publications
- A Phase II Study of AT-101 to Overcome Bcl-2-Mediated Resistance to Androgen Deprivation Therapy in Patients With Newly Diagnosed Castration-Sensitive Metastatic Prost...
- First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.
- Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate Cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinic...
- Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?
- Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate Cancer (mCRPC).
- Erratum to: The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Meta...
- The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adren...
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance).
- A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with Disease progression on or intolerance to tyrosine kinase inhibitor the...
- Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal Cell carcinoma.
- Stereotactic body radiotherapy for the treatment of oligometastatic renal Cell carcinoma.
- An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial Cancer.
- Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma.
- Long-term Survival and Biomarker Correlates of Tasquinimod Efficacy in a Multicenter Randomized Study of Men with Minimally Symptomatic Metastatic Castration-Resistant...
- Phase II Study Of The Oral MEK Inhibitor Selumetinib In Advanced Acute Myeloid Leukemia (AML): A University Of Chicago Phase II Consortium Trial.
- FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell Cancer.
- The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate Cancer: Resu...
- Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic Analysis.
- Estimation of renal cell carcinoma treatment effects from Disease progression modeling.
- Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective Analysis of pooled, prospec...
- Monitoring anti-angiogenic therapy in colorectal Cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
- MR Imaging-guided Focal Laser Ablation for Prostate Cancer: Phase I Trial.
- Evaluation of the Prostate Bed for Local Recurrence After Radical Prostatectomy Using EndoRectal Magnetic Resonance Imaging.
- Renal Cancer therapeutics: now what?
- Diffusion-Weighted and Dynamic Contrast-Enhanced MRI of Prostate Cancer: Correlation of Quantitative MR Parameters With Gleason Score and Tumor Angiogenesis.
- Advantages of genomic complexity: bioinformatics opportunities in microRNA Cancer signatures.
- Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic Disease.
- Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer.
- Phase III Study of Molecularly Targeted Adjuvant Therapy in Locally Advanced Urothelial Cancer of the Bladder Based on p53 Status.
- Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate Cancer.
- Protein-network modeling of prostate Cancer gene signatures reveals essential pathways in disease recurrence.
- Randomized Phase II Trials: A Long-term Investment With Promising Returns.
- Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate Cancers.
- Dasatinib in previously treated metastatic colorectal Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75.
- Baseline patient-reported kidney Cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
- Obese Frailty, Physical Performance Deficits, and Falls in Older Men with Biochemical Recurrence of Prostate Cancer on Androgen Deprivation Therapy: A Case-control Study.
- A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Carcinoma.
- Pazopanib in renal Cell carcinoma.
- A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal Cell carcinoma.
- Prostate cancer: differentiation of central Gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging.
- Bevacizumab and everolimus in renal Cancer: a rational way forward.
- Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial Cancer, a California Cancer Consortium Trial.
- A phase I study of continuous infusion cilengitide in patients with solid Tumors.
- Gemcitabine plus sorafenib in patients with advanced pancreatic Cancer: a phase II trial of the University of Chicago Phase II Consortium.
- WITHDRAWN: Cognitive effects of androgen deprivation therapy in an older cohort of men with prostrate Cancer.
- Comparison of quantitative parameters in cervix Cancer measured by dynamic contrast-enhanced MRI and CT.
- Dose-escalated radiotherapy for high-risk prostate Cancer: outcomes in modern era with short-term androgen deprivation therapy.
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal Cell carcinoma: final results of CALGB 90206.
- Prognosis and prediction in a Facebook world.
- Vorinostat in advanced prostate Cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a s...
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
- Phase II study of axitinib in sorafenib-refractory metastatic renal Cell carcinoma.
- Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a Large phase 2 study.
- Effective therapy for metastatic renal Cancer, whither to now.
- Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal Cancer global evaluation trial.
- Patient anxiety about prostate Cancer independently predicts early initiation of androgen deprivation therapy for biochemical Cancer recurrence in older men: a prospec...
- Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI Analysis.
- Adjuvant chemotherapy in lymph node positive bladder Cancer.
- A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies.
- The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate Cancer.
- Phase II trial of carboplatin and paclitaxel in papillary renal Cell carcinoma.
- Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal Cancer.
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal Cell carcinoma: CALGB 90206.
- Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
- An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic Disease.
- Antitumor activity and biomarker Analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
- Falls and physical performance deficits in older patients with prostate Cancer undergoing androgen deprivation therapy.
- Phase 2 trial of talactoferrin in previously treated patients with metastatic renal Cell carcinoma.
- A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell Cancer.
- Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
- Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate Cancer?: a conceptual review.
- Multiple reference tissue method for contrast agent arterial input function estimation.
- Design of phase II Cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung Cancer.
- Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone...
- A phase II study of ixabepilone (BMS-247550) in metastatic renal-Cell carcinoma.
- The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents.
- A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial Cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II conso...
- A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate Cancer...
- Gene expression profiling in kidney Cancer: combining differential expression and chromosomal and pathway analyses.
- Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder Cancer.
- Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal Cell carcinoma.
- A phase II study of depsipeptide in refractory metastatic renal cell Cancer.
- Combination therapy of imatinib mesylate and interferon-alpha demonstrates minimal activity and significant toxicity in metastatic renal Cell carcinoma: results of a s...
- A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate Cancer patients with bone metastases.
- Novel kinase inhibitors in renal Cell carcinoma: progressive development of static agents.
- New targets, therapies, and toxicities: lessons to be learned.
- Targeted agents for the treatment of advanced renal Cell carcinoma.
- Suppression of metastatic colonization by the context-dependent activation of the c-Jun NH2-terminal kinase kinases JNKK1/MKK4 and MKK7.
- Randomized phase II trials and prostate-specific antigen endpoints in prostate Cancer: much ado about nothing?
- Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic Cancer.
- Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in ren...
- A Phase II study of oxaliplatin in urothelial Cancer.
- A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial Cancer.
- Transcriptional profiles in peripheral blood mononuclear Cells prognostic of clinical outcomes in patients with advanced renal Cell carcinoma.
- Pharmacodynamic Analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or S...
- Estimating the arterial input function using two reference tissues in dynamic contrast-enhanced MRI studies: fundamental concepts and simulations.
- Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-Cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Schools
Yale University
Michael Reese
Michael Reese Hospital and Med Center
University of Chicago
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- America's Top Doctors
- Chicago Magazine: Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Fellow (FACP)
- Super Doctor
Education
-
University of Chicago -
Yale University School of Medicine
Hospital
-
University of Chicago Medical Center
Drug Facts
| NPI NUMBER | 1033272547 | |
| NPPES Provider LastName | STADLER | |
| NPPES Provider FirstName | WALTER | |
| NPPES Provider ZIPCode | 606371447 | |
| NPPES Provider State | IL | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 560.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 71.0 | |
| Percent Opioid Claims | 12.68 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1033272547 |
| Last Name Of The Provider | STADLER |
| First Name Of The Provider | WALTER |
| View All |
Similar Doctors
|
Dr. Rupa Chennamaneni, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley J. Borowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John L. Showel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. VanDerweele, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jessica K. Altman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Silviya V. Velinova, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jyoti D. Patel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vassiliki Saloura, MD
This Doctor is OpenDoctor Recommended.
|